Diagnostic applications of nuclear medicine: Lymphomas

Heather A. Jacene, Sree Harsha Tirumani, Richard L. Wahl

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review


Hodgkin and non-Hodgkin lymphomas are lymphoid neoplasms arising from B cells, T cells, or NK (natural killer) cells. [18F]FDG PET/CT is more accurate for the primary staging of lymphoma, particularly because it can detect disease in normal-sized lymph nodes, liver, spleen, and bone marrow. A major advantage of [18F]FDG PET in determining the outcome of therapy is distinguishing active lymphoma from fibrosis/ necrosis in residual masses. Posttherapy [18F] FDG PET provides important prognostic information and has been incorporated into the currently used criteria for evaluating response to therapy in lymphoma (Lugano/Lyric Classifications). Interim [18F]FDG PET/CT also provides prognostic information and is being evaluated for "risk-adapted therapy" in setting of clinical trials.

Original languageEnglish
Title of host publicationNuclear Oncology
Subtitle of host publicationFrom Pathophysiology to Clinical Applications
PublisherSpringer International Publishing
Number of pages41
ISBN (Electronic)9783319262369
ISBN (Print)9783319262345
StatePublished - Oct 27 2017


  • Hodgkin
  • Lymphoma
  • Response to therapy
  • Staging
  • [F]FDG
  • non-Hodgkin


Dive into the research topics of 'Diagnostic applications of nuclear medicine: Lymphomas'. Together they form a unique fingerprint.

Cite this